Abstract In isolated human platelets, exposure of subtraction 3 high-density lipoprotein (HDL,) binding sites to high concentrations of HDL, (1 mg/mL) causes rapid desensitization of HDL3 (50 jU,g/mL)-stimulated breakdown of phosphatidylcholine, as shown in approximately a 70% depression of the maximal 1,2-diacylglycerol release activity by phospholipase C. This desensitization is HDL, dose dependent (IC 50 , 150±20 ig/mL, n=6) and time dependent (t 1/2 , <30 seconds). It requires the binding of HDL,, as pretreatment of HDL, by tetranitromethane does not cause the desensitization of HDLj-induced phospholipase C activity. Permeabilization of human platelets with 10 /ig/mL digitonin, used to permit access of charged inhibitors to the cytosol, does not interfere with the pattern of HDLj (1 mg/mL) -induced desensitization of HDL, (50 /ig/mL)-stimulated phospholipase C. Inhibitors of protein kinase C (100 /umol/L H-7 and 10 /nmol/L staurosporine) markedly inhibit desensitization of HDL,-induced P revious studies have demonstrated that subtraction 3 high-density lipoprotein (HDL,) binding sites are present on platelet membranes. 13 Koller et al 3 have reported that the glycoprotein Ilb/IIIa complex, the inducible platelet fibrinogen receptor, is able to interact with lipoproteins. HDL3 was found to bind to either the 95-to 110-kD glycoprotein Ilia or to the 136-to 140-kD glycoprotein lib. Glycoprotein lib/ Ilia acts until now as a platelet HDL, binding site.
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Furthermore, HDL 3 binding sites are coupled to phospholipase C (PLC) through pertussis toxin-sensitive GTP binding proteins. 45 In human platelets, HDL 3 binding sites act via the PLC-mediated hydrolysis of phosphatidylcholine and the generation of 1,2-diacylglycerol, which activates the multifunctional enzyme protein kinase C (PKC). The HDL 3 -induced signaling pathway is recorded only when platelets are stimulated by low concentrations of HDL 3 (50 ixglmL). Higher HDL3 concentrations (1 mg/mL) are not able to trigger phosphatidylcholine hydrolysis, indicating a loss of responsiveness. 4 One major form of regulation of the activity of G protein-coupled receptors is desensitization, 6 -9 which is a general biological phenomenon whereby the response phospholipase C activity, whereas cAMP-dependent protein kinase inhibitor (1 ^tmol/L), heparin (100 nmol/L), or concanavalin A (0.25 mg/mL) were ineffective. HDL,-induced desensitization is accompanied at least by the phosphorylation of the 94-and 110-kD proteins. Inhibition of HDL,-induced desensitization by 100 ^.mol/L H-7 or 10 /xmol/L staurosporine is characterized by a marked reduction of the phosphorylation state of these proteins in permeabilized platelets. Whereas protein kinase C inhibitors fully inhibited the phosphorylation of the 94-and 110-kD proteins, inhibitors of protein kinase A were less effective. These data establish that phosphorylation by protein kinase C represent a step in the desensitization of HDL, binding sites in human platelets. (Arterioscler Thromb. to a specific ligand wanes over time despite the continuous presence of the ligand. The impairment of receptor functions is linked to protein phosphorylation, which appears to be a key factor. Most often, homologous desensitization is accompanied by receptor phosphorylation, which triggers the process of functional uncoupling from G proteins. 1012 In addition, a rapid sequestration of the receptors away from the cell surface and a modulation of the expression of the receptor gene itself result in a net decrease in receptor number. 13 Whereas desensitization of the adrenergic system is rather well understood, less is known about receptors coupled to phosphatidylinositol or phosphatidylcholine turnover. 1417 Moreover, until now little has been known about HDL3 binding site regulation. Platelets therefore would seem to provide a good model for the study of putative HDI^-induced desensitization. To investigate the regulation of HDL^-induced signal transduction, we have studied the events surrounding the eventual protein phosphorylation induced by high concentrations of HDL3. This report is the first demonstration of the possibility that in human platelets, a high concentration of HDL3 (1 mg/mL) induces acute desensitization of the signaling pathway induced at a low concentration by a mechanism involving, at least in part, PKC.
nin, paranitrophenol phosphate, and phenylmethylsulfonyl fluoride were from Sigma Chemical Co and silica gel highperformance thin-layer chromatography (TLC) plates from Merck. H-7 was kindly provided by Dr Sergheraert. Other biochemical reagents were from Sigma.
Lipoprotein Isolation
HDL3 was isolated from human serum by standard differential ultracentrifugal flotation 18 (HDL, rf=1.125 to 1.210 g/mL). Its protein content was measured by the procedure of Petersen. 19 The apolipoprotein E constituted less than 0.2% of the total HDL; protein. HDL3 modified with tetranitromethane was prepared as described previously. 20 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) performed on a 7% gel indicated that HDL, was pure from any plasmatic protein contaminants.
Human Platelet Isolation
Platelets were isolated from citrated blood drawn freshly from healthy human donors. After centrifugation at 150g for 20 minutes, the platelet-rich plasma was centrifuged for 15 minutes at 900g, and the platelets were resuspended in a 0.35% bovine serum albumin (wt/vol) buffer containing 137 mmol/L NaCl, 2.7 mmol/L KC1, 0.32 mmol/L NaH 2 PO 4 , 5.6 mmol/L glucose, 11.9 mmol/L NaHCO 3 , 1.3 mmol/L HEPES, 100 /u.mol/L paranitrophenol phosphate, and 5 ^imol/L phenylmethylsulfonyl fluoride, pH 7.4 (HEPES-BSA buffer) at a density of 2.5 xlO 8 cells per milliliter.
[ 3 H] Phosphatidylcholine-Prelabeled Platelets
[ 3 H]Phosphatidylcholine (1.25 /xCi) was pipetted into vials and the solvent was evaporated to leave a thin film. Platelets (10 9 ) were then added and incubated for 60 minutes at room temperature. The specific activity of the preparation was 3500 cpm per 2.5 x 10 s platelets unless otherwise specified. Less than 1/200 of the radioactivity was associated with free lipids and nearly all the radioactivity with the phosphatidylcholine fraction.
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Permeabilization of Human Platelets
Human platelets or [ 3 H]phosphatidylcholine-prelabeled platelets resuspended in HEPES-BSA buffer (2.5xlO 8 cells per milliliter) were permeabilized with 10 jig/mL digitonin as described earlier 21 by stepwise addition until more than 95% of the platelets were trypan blue positive. Permeabilized cells retained their normal microscopic appearance.
Desensitization of HDL, Receptors in Platelets
Permeabilized platelets in HEPES-BSA buffer (or for controls, intact platelets) were incubated at a cell density of 2.5xlO 8 cells per milliliter with or without 1 mg/mL HDL, for 5 minutes or the indicated time at 37°C.
Heparin (100 nmol/L), PKI (1 /i.mol/L), staurosporine (10 ju.mol/L), and H-7 (100 /imol/L) were added to permeabilized platelets 2 minutes before the HDL, stimulation. Pretreatment with ConA was realized before desensitization with 0.25 mg/mL ConA in HEPES-BSA buffer for 20 minutes at 37°C followed by two washes in HEPES-BSA buffer. Cells were then permeabilized and treated as described above. Desensitized platelets were collected by gentle centrifugation (15 minutes at 900g), the desensitization medium was discarded, and platelets were processed for 1,2-diacylglycerol release or protein phosphorylation assays.
1,2-Diacylglycerol Release
After permeabilization and desensitization, 2.5xlO
3 H]phosphatidylcholine-prelabeled platelets suspended in 1 mL HEPES-BSA buffer were exposed to 50 /xg/mL HDL, for 30 seconds. The incubations were terminated by immediate addition of 4 mL ice-cold trichloromethane/methanol (2:1 vol/vol). The lipids were extracted as described by Folch et al 22 and spotted on silica gel 60 thin-layer chromatography plates that were developed with petroleum ether/ethyl ether/acetic acid (90:10:5 vol/vol/vol) to separate 1,2-diacylglycerol. The radioactive spots corresponding to 1,2-diacylglycerol and phosphatidylcholine were cut and processed for radioactivity counting. A good correlation for 1,2-diacylglycerol release was found between the [ 3 H]phosphatidylcholine method and the 1,2-diacylglycerol kinase assay.
23
- 24 1,2-Diacylglycerol release recorded in unstimulated platelets after a 5-minute incubation at 37°C ranged around 100 cpm, for a specific activity of 3500 cpm per 2.5xlO 8 cells.
Protein Phosphorylation in Permeabilized Platelets
Permeabilized platelets (2.5xlO 8 /mL) in HEPES-BSA buffer containing 6 junol/L (3 Ci=110 GBq) of [y-
32 P]ATP were incubated with or without 1 mg/mL HDLj (and staurosporine, H-7, heparin, PKI, or ConA when specified) for 5 minutes at 37°C. The reaction was terminated by being brought to 0°C and centrifuged at 900g for 15 minutes. After two washing steps in HEPES-BSA buffer, the pellet was resuspended in an identical volume of HEPES-BSA buffer. Proteins were precipated by 5 vol cold acetone and incubation at -20°C for 10 minutes. Membrane proteins were pelleted by centrifugation (10 OOOg, 5 minutes). After two repeated precipitation and drying steps, the protein pellet was dissolved in 30 ixL of Laemmli sample buffer 25 at 100°C for 3 to 5 minutes.
SDS-PAGE was performed on 4% to 15% gradient gels using the discontinuous system of Laemmli.
25 Gels were stained with Coomassie brilliant blue, and radiolabeled bands were located by exposure with Kodak X-OMAT K film at -80°C.
As controls, permeabilized platelets were incubated only in the presence of the different kinase inhibitors without any desensitization or activation by HDL3. No protein phosphorylation could be registered in such controls (data not shown).
Results
HDL,-Induced Desensitization
To characterize the involvement of a desensitization phenomenon, we analyzed the effects of HDLj preincubation on HDLj-induced intracellular signals in human platelets. Brief exposure (5 minutes) of [ 3 H]phosphatidylcholine-prelabeled platelets to 1 mg/mL HDLj produced nearly a 70% decrease in the ability of subsequent applications of 50 jtg/mL HDL 3 to induce hydrolysis of phosphatidylcholine into 1,2-diacylglycerol, relative to the control, represented by 50 jug/mL HDl^-stimulated platelets. Fig 1 shows that desensitization was HDLj-concentration dependent. This drop in 1,2-diacylglycerol production was not linked to [ 3 H]phosphatidylcholine exchange between prelabeled platelets and high concentrations of HDL3. The radioactivity of HDLj after a 5-minute incubation in the presence of prelabeled platelets represented less than 1% of the specific activity of the platelet preparation and was not significantly modified by increasing HDL3 concentration. Desensitization of HDL^-induced phosphatidylcholine breakdown was almost complete after a 5-minute exposure to 0.8 mg/mL HDL, (IC 50 , 150±20 /ig/mL, n=6). tetranitromethane for 5 minutes before measurement of 50 /ig/mL HDL,-induced PLC activity (Fig 3) . 1,2-Diacylglycerol release was similar to the 1,2-diacylglycerol control value of 50 ^ig/mL HDL^-stimulated platelets. Tetranitromethane abolished HDL 3 binding to platelet membranes and the ability of 1 mg/mL HDL3 to reduce PLC activity.
Effects of Protein Kinase Modulators on HDL,-Induced Desensitization
To determine whether HDL^-induced desensitization is associated with protein phosphorylation, we tested different inhibitors to analyze the contribution of different protein kinases to HDI^-induced desensitization of PLC activity.
Permeabilization with digitonin (10 /ig/mL) was performed to provide inhibitor access to the cytosol, while leaving HDLj-induced desensitization unaltered. In digitonin-permeabilized platelets, the extent of maximal 1,2-diacylglycerol release over basal activity was reduced by HDL, (1 mg/mL) pretreatment to 50% of HDL3 (50 ^g/mL)-stimulated PLC activity. This result was similar to unpermeabilized control values, indicating that digitonin does not interfere with the pattern of HDL3-induced desensitization (Fig 4) . To address the potential role of protein kinasedependent phosphorylation of proteins in producing receptor desensitization, we tested the prevention of HDL3 (1 mg/mL)-induced desensitization in the presence of 1 /imol/L PKI (protein kinase A [PKA] inhibitor), 100 ,Limol/L H-7 or 10 /xmol/L staurosporine (PKC inhibitors), or 100 nmol/L heparin (low-density lipoprotein receptor kinase and /3-adrenergic receptor kinase inhibitor). Results are summarized in Fig 5. PKI and heparin alone did not prevent desensitization or regulation of the HDL3 binding site-coupled 1,2-diacylglycerol release. PKI even seemed to slightly potentiate desensitization; however, 1,2-diacylglycerol release under these conditions was not significantly different from 1,2-diacylglycerol content in unstimulated platelets. In sharp contrast, the HDL3 (1 mg/mL)-induced desensitization of the HDL3 binding site-coupled response was fully blocked by both H-7 and staurosporine. When desensitization was performed in the presence of H-7 or staurosporine, it did not modify the ability of subsequent applications of 50 jug/mL HDL^ to induce hydrolysis of phosphatidylcholine into 1,2-diacylglycerol. Moreover, a slight increase in 1,2-diacylglycerol production was recorded. Incubation of platelets in the presence of the PKC inhibitors alone did not induce significant 1,2-diacylglycerol release (UC-ST or UC-H7). When PKC inhibitors were added together with 50 fig/mL HDL 3 during the platelet activation step (C-H7, C-ST), they did not impair 1,2-diacylglycerol release, indicating that PKC is not involved in the early phase of 1,2-diacylglycerol release. These results are in good agreement with our previous data 4 indicating the involvement of PKC only in the late phase of 1,2-diacylglycerol generation.
The use of inhibitors identifies this HDL,-induced desensitization of PLC activity at least in part as PKC mediated. First, it can be completely blocked by the presence of H-7 or staurosporine, and second, it is not counteracted by PKI or heparin.
Effects of ConA on HDL 3 -Induced Desensitization
As a second step, we sought to determine whether HDL3 binding sites are sequestered away from the cell surface into a membrane-associated compartment as for )3-adrenergic receptors.
26 HDL3 (50 /ig/mL)-induced 1,2-diacylglycerol production was measured in permeabilized platelets pretreated with 0.25 mg/mL ConA (known to block sequestration) before the desensitization step with HDL3 (1 mg/mL). Fig 5 shows that in the context of the processes studied here, pretreatment by ConA does not modify or produce even a modest reduction in HDL3 (50 /xg/mL)-induced 1,2-diacylglycerol production compared with desensitized controls. This suggests that HDL3 binding site sequestration is not the main event of HDI^-induced desensitization.
Desensitization-Induced Protein Phosphorylation
Desensitization could be in general associated with either receptor, G protein, or effector phosphorylation. 10 To show whether HDI^-induced desensitization is linked to protein phosphorylation, digitonin-permeabilized platelets were incubated in the presence of 6 fimolfL [ 32 P]ATP (3 Ci=110 GBq) and 1 mg/mL HDL, for 5 minutes at 37°C. Membrane proteins were separated by SDS-PAGE and processed for autoradiography (Fig 6) . Among the few protein bands (94,110,120,140, 158 kD) that were detectable after autoradiography, two proteins (94 and 110 kD) were highly phosphorylated only in desensitized platelet extracts compared with platelets stimulated only by 50 /xg/mL HDL3.
The addition of different kinase inhibitors to the desensitization medium subsequently modified the phosphorylation state of the previously labeled proteins. When 1 /unol/L PKI was added, the apparent steady-state level of protein phosphorylation was slightly decreased. In contrast, the addition of both 100 /xmol/L H-7 or 10 /xmol/L staurosporine had a marked effect on the 94-and 110-kD protein phosphorylation. No phosphorylation of these proteins was found when desensitization was performed in the presence of PKC inhibitors.
These results again suggest that desensitization involves at least in part a PKC-dependent phosphorylation of both 94-and 110-kD proteins.
Discussion
In a previous article, 4 we demonstrated that HDL, (50 /xg/mL)-induced 1,2-diacylglycerol production in [ [ 3 H]Phosphatidylcholine-labeled platelets were permeabilized with 10 i±glmL digitonin and desensitized in the presence of 1 mg/mL HDL 3 and various inhibitors as described in "Methods." After 5 minutes of desensitization, 50 jig HDL 3 -induced 1,2-diacylglycerol (DAG) formation was assayed. Controls refer to HDL 3 (50 /xg/mL)-induced DAG release in the absence of any pretreatment (C) or in the presence of staurosporine (C-ST) or H-7 (C-H7); after desensitization (D) performed in the presence of H-7 (H7), staurosporine (ST), cAMP-dependent protein kinase inhibitor (PKI), or heparin (HE); or after a 30-(ConA1) or 120-(ConA2) second pretreatment with concanavalin A. Results are mean±SD of three experiments performed in duplicate. 1,2-DAG content in unstimulated platelets was determined in separate experiments performed in duplicate without any inhibitors (UC) or in the presence of H-7 (UC-H7) or staurosporine (UC-ST) for 30 seconds at 37 °C. tered with HDL3 modified with tetranitromethane and is concentration dependent in the range of 0 to 0.7 mg/mL HDL3, with half-maximal and maximal responses occurring at 0.15 and 0.60 mg/mL HDL3, respectively. Stimulation with higher HDL3 concentrations resulted in a gradual decline in 1,2-diacylglycerol production. 4 Similar decreases in agonist-stimulated receptor activity have resulted in a loss of responsiveness of the system, also termed desensitization. 10 As HDL3 promotes phosphatidylcholine hydrolysis, the accompanying release of 1,2-diacylglycerol may activate PKC and at the same time switch on a feedback loop that can uncouple ligand and binding sites from PLC activation. This idea is supported by the observations that (1) high concentrations of HDL3 fail to activate PLC, 4 (2) HDL3 internalization within platelets is encountered for higher concentrations 1 compared with other HDI^-internalizing cells, 27 and (3) platelet stimulation by phorbol esters can stimulate a delayed phosphatidylcholine hydrolysis through a PKC-dependent pathway. 4 HDl^-induced desensitization in human platelets was assessed by quantifying the signal transduction efficacy of the system after exposure of HDL3 binding sites to physiological agonist concentrations. A brief exposure of [
3 H]phosphatidylcholine-prelabeled platelets to HDLj (1 mg/mL) acutely impairs the ability of a subsequent application of HDL3 (50 jig/mL) to induce phosphatidylcholine breakdown. Almost complete desensitization is obtained in 5 minutes with a 1 mg/mL HDL, pretreatment. Moreover, HDL^-induced desensitization is time and dose dependent.
HDLj-induced desensitization of PLC activity is mediated by the binding of HDL3, as HDL3 pretreatment with tetranitromethane abolishes both HDL3 binding to the cell surface and desensitization of HDL^-induced PLC activity. Indeed, a 5-minute preincubation of platelets in the presence of 1 mg/mL HDL3 modified with tetranitromethane does not suppress the ability of 50 /ig/mL HDL3 to induce phosphatidylcholine breakdown.
Current studies 610 suggest that protein phosphorylation by cellular kinases and receptor sequestration are important components of the early events of desensitization. In human platelets, recent investigations suggest that activation of PKC is also able to desensitize the action of thrombin. 17 By applying different sequestration or protein kinase inhibitors to digitonin-permeabilized platelets, we investigated the contribution of these processes to HDI^-induced desensitization. PKA-dependent phosphorylation could be selectively inhibited by PKI or sequestration by ConA. Despite the fact that H-7 and staurosporine lack specificity for PKC over several other kinases, they remain popular tools for examining the role of PKC in regulating cell functions. Heparin was purposely used as an inhibitor of /3-adrenergic receptor or low-density lipoprotein receptor kinase and was not supposed to impair HDI^-induced desensitization.
Impairment of HDL 3 -induced desensitization by inhibitors was analyzed by 1,2-diacylglycerol assay to determine HDL^-induced PLC activity and by the uptake of 32 P into platelets and incorporation into substrates of interest. To determine whether HDI^-induced desensitization is associated with any change in protein phosphorylation, we incubated platelets during the desensitization step in the presence of [ 32 P]ATP. Autoradiography of SDS-PAGE-separated membrane proteins indicates that some protein phosphorylation is achieved only in desensitized platelets compared with control platelets stimulated only with 50 /xg/mL HDL3. The apparent molecular masses of the two major phosphorylated protein bands are 94 and 110 kD. Among the three candidate proteins (ie, HDL3 binding sites, G proteins, and PLC) that could be phosphorylated during desensitization, G proteins and PLC do not fit with the molecular mass characteristics of the phosphorylated protein bands. Relevance of the 94-or 110-kD protein to HDL3 binding sites is a conceivable hypothesis awaiting further confirmation.
Recently it has been reported that platelet activation induces tyrosine phosphorylation of three specific proteins with apparent molecular masses of 84, 95, and 97 kD, 28 but it is likely that in our experiments protein phosphorylation was unrelated to inadvertent platelet activation during washing and centrifugation steps, as no protein labeling was recorded in controls. These findings clearly indicate that specific protein phosphorylation occurs during the desensitization process of HDI^-induced 1,2-diacylglycerol generation.
Pretreatment with ConA, known to abolish sequestration, was unsuccessful in reducing HDL^-induced desensitization of PLC activity, indicating that the contribution of sequestration to HDL3 binding site regulation was not significant at 1 mg/mL HDL3. Previously, Lohse et al 7 demonstrated that sequestration of /3-adrenergic receptors occurs at high concentrations of agonist and that pretreatment with ConA has no significant effect if the phosphorylation mechanism is operative.
Pretreatment of platelets with heparin does not impair desensitization of HDL, (50 /LAg/mL)-induced PLC activity, in any of its kinase inhibitor or other roles.
Among all the kinase inhibitors, only PKC inhibitors are able to counteract HDL,-induced desensitization, which is fully blocked. After a 5 -minute desensitization in the presence of H-7 or staurosporine, 50 /xg/mL HDL3 is able to activate PLC activity and induce 1,2-diacylglycerol release from phosphatidylcholine. These findings suggest that the binding of HDL3 can produce 1,2-diacylglycerol in human platelets but that at a physiological concentration of the agonist, the signaling pathway may be desensitized acutely by a PKC-mediated feedback system. Moreover, H-7 and staurosporine fully block the phosphorylation of 94-and 110-kD proteins during desensitization of platelets to HDL3.
In sharp contrast, PKA inhibitors are not able to counteract HDL 3 -induced desensitization. Furthermore, a slight decrease in PLC activity was registered when desensitization was performed in the presence of PKI, suggesting that PKA could control HDL,-induced PLC activity. However, this speculation appears less likely, as the decrease in 1,2-diacylglycerol content is not significant when compared with the 1,2-diacylglycerol content of unstimulated platelets. Phosphorylation of 94-and 110-kD proteins is decreased when desensitization is performed in the presence of PKA inhibitors, whereas proteins of a higher molecular mass are slightly phosphorylated. Various forms of cross talk between kinases or phosphatases and other signaling cascades have been observed in other situations, but it is far too speculative to ascertain the role of PKA, if any, in HDLj-induced desensitization of PLC activity in human platelets.
If the HDL3 binding proteins represent glycoprotein Ilb/IIIa, one would anticipate a relation between HDL3 binding and glycoprotein Ilb/IIIa complex activation. To ascertain whether HDL3 fulfills any role in controlling glycoprotein Ilb/IIIa functions requires a better characterization of the HDL3 binding proteins that are phosphorylated in human platelets.
In summary, we have provided evidence that exposure of platelets to 1 mg/mLHDLj impairs HDI^-induced PLC activity at least by a PKC-mediated feedback system and that the binding of high concentrations of HDL, to their binding sites induces a mechanism that reduces platelet responsiveness to low-intensity stimulation.
